trending Market Intelligence /marketintelligence/en/news-insights/trending/w82np1h9tpm0ywjds1jv3q2 content esgSubNav
In This List

EyeGate Pharmaceuticals names director

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


EyeGate Pharmaceuticals names director

EyeGate Pharmaceuticals Inc. appointed Steven Boyd to its board.

Boyd is the chief investment officer of Armistice Capital, a New York-based equity hedge fund focused on the healthcare and consumer sectors.

Waltham, Mass.-based EyeGate is a clinical-stage specialty pharmaceutical company developing therapies to treat eye-related diseases and disorders.